Moderate harm outcomes such as cholelithiasis (1.90, 1.12–3.22), alopecia (5.67, 2.47–13.00) and cholecystitis (12.00, 1.62–88.85) were also higher in the GLP-1 RA group, while pancreatitis (1.87, 0.52–6.67) was not statistically different between the treatment groups. The gene discussed is GLP1R; the disease is cholelithiasis.